• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Assessing the efficacy and safety of sequential intravesical gemcitabine and docetaxel - does time from transurethral resection of bladder tumour to induction matter?

作者信息

McElree Ian M, Henning Grant M, Steinberg Ryan L, Hougen Helen Y, Mott Sarah L, O'Donnell Michael A, Packiam Vignesh T

机构信息

Carver College of Medicine, University of Iowa, Iowa City, IA, USA.

Department of Urology, Mayo Clinic, Rochester, MN, USA.

出版信息

BJU Int. 2025 Jul;136(1):42-44. doi: 10.1111/bju.16716. Epub 2025 Mar 21.

DOI:10.1111/bju.16716
PMID:40118650
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12134428/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33f/12134428/63b580e7f8e9/BJU-136-42-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33f/12134428/63b580e7f8e9/BJU-136-42-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33f/12134428/63b580e7f8e9/BJU-136-42-g001.jpg

相似文献

1
Assessing the efficacy and safety of sequential intravesical gemcitabine and docetaxel - does time from transurethral resection of bladder tumour to induction matter?评估序贯膀胱内吉西他滨和多西他赛的疗效和安全性——从经尿道膀胱肿瘤切除到诱导治疗的时间是否重要？
BJU Int. 2025 Jul;136(1):42-44. doi: 10.1111/bju.16716. Epub 2025 Mar 21.
2
Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study.序贯膀胱内吉西他滨+多西他赛与卡介苗治疗非肌层浸润性膀胱癌的生活质量、疗效和安全性：一项初步研究。
Urol Int. 2022;106(8):784-790. doi: 10.1159/000524098. Epub 2022 Jun 2.
3
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.序贯膀胱内吉西他滨和多西他赛治疗卡介苗初治高危非肌层浸润性膀胱癌。
J Urol. 2022 Sep;208(3):589-599. doi: 10.1097/JU.0000000000002740. Epub 2022 Jul 27.
4
A Comparison Between Intravesical Gemcitabine Plus Docetaxel and Intravesical Bacillus Calmette-Guérin in the Treatment of Nonmuscle Invasive Naive Urinary Bladder Cancer: A Systematic Review and Meta-analysis of Oncological Outcomes.吉西他滨联合多西他赛膀胱灌注与卡介苗膀胱灌注治疗初发非肌层浸润性膀胱癌的疗效比较：肿瘤学结局的系统评价与Meta分析
Urology. 2025 May;199:171-178. doi: 10.1016/j.urology.2025.01.004. Epub 2025 Jan 9.
5
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer.吉西他滨和多西他赛序贯膀胱内灌注与卡介苗治疗卡介苗无反应性非肌层浸润性膀胱癌患者的肿瘤学结局比较
Eur Urol Oncol. 2025 Apr;8(2):469-476. doi: 10.1016/j.euo.2024.12.005. Epub 2024 Dec 17.
6
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer.顺行膀胱内吉西他滨和多西他赛与卡介苗治疗高危非肌肉浸润性膀胱癌患者的比较。
JAMA Netw Open. 2023 Feb 1;6(2):e230849. doi: 10.1001/jamanetworkopen.2023.0849.
7
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.多机构评价吉西他滨和多西他赛序贯治疗非肌肉浸润性膀胱癌的挽救疗法。
J Urol. 2020 May;203(5):902-909. doi: 10.1097/JU.0000000000000688. Epub 2019 Dec 10.
8
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.经单次诱导卡介苗（BCG）治疗后复发的非肌肉浸润性膀胱癌患者中，膀胱内序贯吉西他滨和多西他赛与卡介苗加干扰素的比较。
Urol Oncol. 2022 Jan;40(1):9.e1-9.e7. doi: 10.1016/j.urolonc.2021.03.024. Epub 2021 Jun 4.
9
Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette-Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study.经尿道膀胱肿瘤切除术治疗中高危膀胱癌患者后行膀胱内吉西他滨与卡介苗诱导治疗的复发率比较分析：一项回顾性多中心研究。
Investig Clin Urol. 2024 May;65(3):248-255. doi: 10.4111/icu.20230313.
10
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.顺次膀胱内给予吉西他滨/多西他赛在卡介苗治疗后复发的高危非肌层浸润性膀胱癌患者中提供持久缓解。
Urol Oncol. 2023 Nov;41(11):458.e1-458.e7. doi: 10.1016/j.urolonc.2023.06.018. Epub 2023 Sep 9.

本文引用的文献

1
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.非肌层浸润性膀胱癌的诊断与治疗：美国泌尿外科学会/泌尿外科学会指南：2024年修订版
J Urol. 2024 Apr;211(4):533-538. doi: 10.1097/JU.0000000000003846. Epub 2024 Jan 24.
2
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer.序贯膀胱内吉西他滨和多西他赛是卡介苗治疗中危非肌肉浸润性膀胱癌的替代方案。
Eur Urol Oncol. 2023 Oct;6(5):531-534. doi: 10.1016/j.euo.2023.06.011. Epub 2023 Jul 18.
3
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer.
顺行膀胱内吉西他滨和多西他赛与卡介苗治疗高危非肌肉浸润性膀胱癌患者的比较。
JAMA Netw Open. 2023 Feb 1;6(2):e230849. doi: 10.1001/jamanetworkopen.2023.0849.
4
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).欧洲泌尿外科学会非肌层浸润性膀胱癌（Ta、T1和原位癌）指南
Eur Urol. 2022 Jan;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010. Epub 2021 Sep 10.
5
Prognostic Implications of Treatment Delays for Patients with Non-muscle-invasive Bladder Cancer.非肌层浸润性膀胱癌患者治疗延迟的预后意义。
Eur Urol Focus. 2022 Sep;8(5):1226-1237. doi: 10.1016/j.euf.2021.06.007. Epub 2021 Jun 23.
6
Time interval from transurethral resection of bladder tumour to bacille Calmette-Guérin induction does not impact therapeutic response.经尿道膀胱肿瘤切除术与卡介苗诱导之间的时间间隔不会影响治疗反应。
BJU Int. 2021 Nov;128(5):634-641. doi: 10.1111/bju.15413. Epub 2021 May 5.
7
Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes.经尿道膀胱肿瘤切除术治疗非肌肉浸润性膀胱癌后延迟卡介苗免疫治疗的起始时间与不良生存结局相关。
World J Urol. 2021 Jul;39(7):2545-2552. doi: 10.1007/s00345-020-03522-3. Epub 2020 Nov 23.
8
Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer.非肌层浸润性膀胱癌经尿道膀胱肿瘤切除术后单剂量膀胱内注射吉西他滨的全身吸收和药代动力学
Urology. 2009 Nov;74(5):1078-83. doi: 10.1016/j.urology.2009.05.094. Epub 2009 Sep 20.